Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Just Flying Around

<< Previous

Bullboard Posts

Next >>

Post by crow27on Feb 09, 2021 2:47pm

332 Views

Post# 32515412

Just Flying Around

The Crow said the news would come out of no-where. Now those $3.50 shares look awfully good.
Anyway, the road looks paved to $15.00 min. This was a blockbuster deal that leads the way to the Nasdaq. Just wait until the markets digest this .................... it's only 7 hours old??
Wait till they ring that Nasdaq BELL!!! hahaha.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing